Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

PR Newswire03-13

Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1 Approval follows a positive Committee for Medicinal Products for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2519007017?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-13 16:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2519007017","market":"nz","top_or_hot":-1,"title":"Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older","media":"PR Newswire","content":"<div>\n<p>Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1\nApproval follows a positive Committee for Medicinal Products for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-13 16:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1\nApproval follows a positive Committee for Medicinal Products for ...</p>\n\n<a href=\"https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EC","symbol_name":"哥伦比亚国家石油","start_time":0,"source_url":"https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html","article_id":"2519007017","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2519007017","pubTimestamp":1741855500,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1. Approval follows a positive Committee for Medicinal Products for Human Use  opinion from the European Medicines Agency in January 20252. Treatment with brexpiprazole  significantly reduced the symptoms of schizophrenia as measured by PANSS total score compared to placebo3. WINDSOR, England and VALBY, Denmark, March 13, 2025 /PRNewswire/ --Otsuka Pharmaceutical Europe Ltd.  and H. Lundbeck A/S  today announced that the European Commission  has approved Rxulti for the treatment of schizophrenia in adolescents aged 13 years and older.1 Brexpiprazolewas previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.4. Brexpiprazole was discovered by Otsuka and is being co-developed and co-commercialised under a collaboration and license agreement between Otsuka Pharmaceutical Europe Ltd. a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"EC":"哥伦比亚国家石油","BK4007":"制药","BK4201":"综合性石油与天然气企业","HLUBF":"H. Lundbeck A/S","BK4087":"商业印刷","HLBBF":"H. Lundbeck A/S","CHMP":"冠军工业"},"translate_title":"Rxulti®（brexpiprazole）在欧盟获批用于治疗13岁及以上青少年精神分裂症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHMP":1,"EC":1,"HLBBF":0.9,"HLUBF":0.9},"content_text":"Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1\nApproval follows a positive Committee for Medicinal Products for Human Use (CHMP) opinion from the European Medicines Agency in January 20252\nTreatment with brexpiprazole (2-4 mg/day) significantly reduced the symptoms of schizophrenia as measured by PANSS total score compared to placebo3\n\nWINDSOR, England and VALBY, Denmark, March 13, 2025 /PRNewswire/ -- Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.1 Brexpiprazole was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.4\nThe EC decision based its approval on a 6-week, randomised, double-blind placebo-controlled and active-referenced trial of 316 adolescent patients, which evaluated the efficacy and safety profile of the drug as primary and secondary outcomes, respectively.3 Brexpiprazole (2-4mg/day) was associated with greater reductions in symptom severity, as measured by the Positive and Negative Syndrome Scale (PANSS) total score compared with placebo in patients aged 13 years and older, and was generally well tolerated with a safety profile consistent with that seen in adult patients with schizophrenia.3\nAndy Hodge, CEO at Otsuka Pharmaceutical Europe, said: \"The prognosis for adolescence-onset schizophrenia is poor compared with adult-onset schizophrenia and can be associated with more chronic and severe symptoms. We welcome the EC decision to extend the indication for brexpiprazole to include adolescents aged 13 years and older, providing young people in Europe with another much-needed treatment option.\"\nJohan Luthman, EVP and Head of Research & Development at Lundbeck, said: \"Today marks a major milestone for young patients, caregivers, and families navigating the complexities of schizophrenia. This approval is testament to our commitment and unwavering support to lessen the disease burden for patients and caregivers in the EU, by providing a treatment option with proven efficacy and tolerability.\"\nAbout Rxulti® (brexpiprazole)\nBrexpiprazole is an atypical oral antipsychotic that is taken once a day.3 The pharmacology of brexpiprazole is believed to be mediated by a modulatory activity at the serotonin and dopamine systems that combines partial agonist activity at serotonergic 5-HT1A and at dopaminergic D2 receptors with antagonist activity at serotonergic 5-HT2A receptors, with similar high affinities at all of these receptors. Brexpiprazole also shows antagonist activity at noradrenergic α1B/2C receptors with affinity in the same sub-nanomolar Ki range.4,5\nBrexpiprazole was discovered by Otsuka and is being co-developed and co-commercialised under a collaboration and license agreement between Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S.\nBrexpiprazole was previously approved in the European Union in 2018 for the treatment of adult patients with schizophrenia.4\nAbout schizophrenia\nSchizophrenia is a chronic, disabling and progressive mental illness, characterised by delusions, hallucinations, and disordered cognition which may occur at varying intervals between periods of relative symptomatic stability.5,7 Schizophrenia affects approximately 24 million people, or 1 in 300 people (0.32%) worldwide.8 Onset is most often during late adolescence and the twenties, and onset tends to happen earlier among men than women.8\nSchizophrenia is frequently associated with significant distress and impairment in personal, family, social, educational, occupational, and other important areas of life.8 It is one of the top 15 leading causes of disability worldwide.9For adolescents with schizophrenia, antipsychotics offer improvements in symptom control; however, younger patients may be particularly vulnerable to side effects.10,11,12\nAbout Otsuka\nOtsuka Pharmaceutical is a global healthcare company with the corporate philosophy: \"Otsuka-people creating new products for better health worldwide.\"\nOtsuka researches, develops, manufactures, and markets innovative products, focusing on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programmes in several under-addressed diseases including tuberculosis, a significant global public health issue.\nOtsuka Europe employs around 500 people and focuses on psychiatric and neurologic disorders, nephrology and immunology, haemato-oncology, and digital therapeutics. Otsuka Pharmaceutical Europe Ltd. is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. \nThe Otsuka group of companies employ approximately 35,340 people worldwide with consolidated sales of approximately € 14.1 billion and a spend of € 1.9 billion on research and development in 2024. For further information on Otsuka, please visit www.otsuka-europe.com.\nOtsuka contact for mediaAlison RossOtsuka Pharmaceutical Europe Ltd.ARoss@Otsuka-Europe.com+44 776 833 7128\nAbout H. Lundbeck A/S\nLundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.\nBrain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.\nAs a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.\nWe are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.\nLundbeck has approximately 5,500 employees in more than 50 countries and our products are available in more than 80 countries.\nLundbeck contactsInvestors: Jens HøyerVice President, Head of Investor Relations,JSHR@lundbeck.com+45 30 83 45 01Media:Åsa JosefssonSenior Director, Corporate Communication,asjs@lundbeck.com+45 30 83 42 50\nReferences\n\nEuropean Commission. Rxulti Product Information. Available at: https://ec.europa.eu/health/documents/community-register/html/h1294.htm Accessed: March 2025. Rxulti positive CHMP opinion. Available at: https://www.ema.europa.eu/en/medicines/human/variation/rxulti Accessed: February 2025.\nWard C, et al. Oral presentation at the 2024 Annual Congress of the Schizophrenia International Research Society, Florence, Italy.\nRxulti SmPC. Available from: https://www.ema.europa.eu/en/documents/product-information/rxulti-epar-product-information_en.pdf Accessed: February 2025.\nMaeda K, et al. J Pharmacol Exp Ther 2014; 350 (3): 589–604.\nJain R, et al. J Clin Psychiatry 2024; 85 (4): plunaro2417ah.\nKahn RS, et al. Nat Rev Dis Primers 2015; 1 (15067). \nWorld Health Organisation. Factsheet, Schizophrenia. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia Accessed: February 2025.\nGlobal Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1211–1259.\nMcClellan J & Stock S. J Am Acad Child Adolesc Psychiatry 2013; 52 (9): 976–90.\nOlfson M, et al. Arch Gen Psychiatry 2012; 69 (12): 1247–56.\nPagsberg AK, et al. J Am Acad Child Adolesc Psychiatry 2017; 56 (3): 191–202.\n\nH. Lundbeck A/SOttiliavej 9, 2500 Valby, Denmark+45 3630 1311info@lundbeck.com\nThis information was brought to you by Cision http://news.cision.com.\nhttps://news.cision.com/h--lundbeck-a-s/r/rxulti---brexpiprazole--approved-in-the-european-union-for-the-treatment-of-schizophrenia-in-adolesc,c4118110\nThe following files are available for download:\n\n\n\n\nhttps://mb.cision.com/Main/18215/4118110/3317559.pdf \nRxulti® approved in the European Union for the treatment of schizophrenia in adolescents \n\n\n\n\n View original content:https://www.prnewswire.co.uk/news-releases/rxulti-brexpiprazole-approved-in-the-european-union-for-the-treatment-of-schizophrenia-in-adolescents-aged-13-years-and-older-302400911.html","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2519007017"}